Jeppe Hagstrup Christensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10601145/publications.pdf

Version: 2024-02-01

33 papers 1,520 citations

430442 18 h-index 395343 33 g-index

33 all docs 33 docs citations

33 times ranked 1484 citing authors

#	Article	IF	CITATIONS
1	Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. BMJ: British Medical Journal, 1996, 312, 677-678.	2.4	195
2	Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with nâ°'3 fatty acids. American Journal of Clinical Nutrition, 1999, 70, 331-337.	2.2	165
3	Fish Consumption, n-3 Fatty Acids in Cell Membranes, and Heart Rate Variability in Survivors of Myocardial Infarction With Left Ventricular Dysfunction. American Journal of Cardiology, 1997, 79, 1670-1673.	0.7	154
4	Marine n-3 Fatty Acids, Wine Intake, and Heart Rate Variability in Patients Referred for Coronary Angiography. Circulation, 2001, 103, 651-657.	1.6	138
5	N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: A Randomized, Placebo-Controlled Intervention Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 780-786.	2.2	132
6	C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. American Journal of Cardiology, 2001, 88, 1139-1142.	0.7	130
7	The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. American Journal of Kidney Diseases, 2004, 44, 77-83.	2.1	69
8	Heart rate variability and plasma lipids in men with and without ischaemic heart disease. Atherosclerosis, 1999, 145, 181-186.	0.4	61
9	Omega-3 Polyunsaturated Fatty Acids and Heart Rate Variability. Frontiers in Physiology, 2011, 2, 84.	1.3	60
10	The autonomic nervous system and cardiovascular disease: role of n-3 PUFAs. Vascular Pharmacology, 2015, 71, 1-10.	1.0	45
11	n-3 Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defibrillators. Europace, 2005, 7, 338-344.	0.7	38
12	Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica, 2008, 93, 892-899.	1.7	38
13	Câ€Reactive Protein Is Associated with Heart Rate Variability. Annals of Noninvasive Electrocardiology, 2007, 12, 216-222.	0.5	30
14	Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis, 2008, 196, 420-424.	0.4	26
15	Soluble adhesion molecules and marine n-3 fatty acids in patients referred for coronary angiography. Atherosclerosis, 2005, 180, 327-331.	0.4	25
16	The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. European Journal of Nutrition, 2009, 48, 1-5.	1.8	25
17	Alpha-linolenic acid and heart rate variability in women examined for coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 345-351.	1.1	23
18	HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacological Research, 2002, 45, 479-483.	3.1	21

#	Article	IF	CITATIONS
19	The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial. Lipids in Health and Disease, 2016, 15, 216.	1.2	19
20	nâ^'3 fatty acids, heart rate variability, and sudden cardiac death. Lipids, 2001, 36, S115-S118.	0.7	17
21	Statins, Ventricular Arrhythmias and Heart Rate Variability in Patients with Implantable Cardioverter Defibrillators and Coronary Heart Disease. Cardiology, 2005, 104, 210-214.	0.6	16
22	The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. International Journal of Cardiology, 2006, 111, 436-441.	0.8	14
23	Intravenous infusion of n-3 polyunsaturated fatty acids and inducibility of ventricular tachycardia in patients with implantable cardioverter defibrillator. Europace, 2010, 12, 941-946.	0.7	13
24	n-3 fatty acids and the risk of sudden cardiac death. Emphasis on heart rate variability. Danish Medical Bulletin, 2003, 50, 347-67.	0.1	13
25	Fish, marine n-3 polyunsaturated fatty acids and coronary heart disease: A minireview with focus on clinical trial data. Prostaglandins Leukotrienes and Essential Fatty Acids, 2006, 75, 191-195.	1.0	12
26	Effect of Intravenous ωâ€3 Fatty Acid Infusion and Hemodialysis on Fatty Acid Composition of Free Fatty Acids and Phospholipids in Patients With Endâ€Stage Renal Disease. Journal of Parenteral and Enteral Nutrition, 2011, 35, 97-106.	1.3	10
27	Adhesion molecules and C-reactive protein are associated to adverse events in angina pectoris. Scandinavian Cardiovascular Journal, 2010, 44, 153-160.	0.4	8
28	n-3 polyunsaturated fatty acids, lipids and lipoproteins in end-stage renal disease. Clinical Lipidology, 2011, 6, 563-576.	0.4	7
29	Long-chain n-3 polyunsaturated fatty acids and coronary heart disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2000, 3, 109-115.	1.3	5
30	The Effect of Marine n-3 Polyunsaturated Fatty Acids on Heart Rate Variability in Renal Transplant Recipients: A Randomized Controlled Trial. Nutrients, 2019, 11, 2847.	1.7	5
31	Cuff inflation during ambulatory blood pressure monitoring and heart rate. Integrated Blood Pressure Control, 2008, Volume 1, 15-19.	0.4	3
32	Adiponectin and marine nâ^'3 fatty acids in patients referred for coronary angiography. International Journal of Cardiology, 2009, 135, 248-250.	0.8	2
33	Omega-3 Polyunsaturated Fatty Acids and Clinical Trials. American Journal of Kidney Diseases, 2011, 57, 352.	2.1	1